Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Renalytix American Depository Receipt RNLXY

Healthcare Medical Devices
Renalytix plc is a United Kingdom-based company, which is engaged in the development of artificial intelligence-enabled clinical diagnostic solutions for kidney disease. The Company is engaged in a field of bioprognosis for kidney health. The Company has engineered a solution that enables early-stage chronic kidney disease progression risk assessment. The Company’s lead product, KidneyIntelX... see more

Recent & Breaking News (OTCQB:RNLXY)

Renalytix to Report Financial Results for Fourth Quarter and Full Year Fiscal 2022 on October 31

GlobeNewswire October 24, 2022

KidneyIntelX Clinical Utility and Health Economics Validated in Multiple Data Releases at American Society of Nephrology

GlobeNewswire October 17, 2022

Renalytix Announces Change to Board of Directors

GlobeNewswire September 20, 2022

Renalytix to Present at H.C. Wainwright 24th Annual Global Investment Conference

GlobeNewswire September 8, 2022

Data Results Published in American Journal of Managed Care demonstrate adoption and clinical utility of KidneyIntelX(TM) with Primary Care Physicians

GlobeNewswire August 8, 2022

Renalytix Reports Financial Results for Third Quarter of Fiscal Year 2022

GlobeNewswire June 30, 2022

Renalytix to Report Financial Results for Third Quarter Fiscal 2022 on June 30

GlobeNewswire June 23, 2022

1,112 Patient Study Demonstrates Clinical Utility and Care Benefits of KidneyIntelX(TM) Risk Stratification in Stage 1 to 3 Diabetic Kidney Disease Patients

GlobeNewswire June 10, 2022

Renalytix to Present at 42nd Annual William Blair Growth Stock Conference

GlobeNewswire June 8, 2022

KidneyIntelX(TM) Demonstrates Ability to Assess Risk of Heart Failure Hospitalization and Death in Large International Diabetic Kidney Disease Patient Cohort

GlobeNewswire June 6, 2022

Renalytix Announces Two Data Presentations on KidneyIntelX(TM) at American Diabetes Association 82nd Scientific Sessions®

GlobeNewswire June 2, 2022

AeroClean Announces Appointment of Timothy J. Scannell to Board of Directors

GlobeNewswire May 12, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Renalytix Plc - RNLX

PR Newswire April 23, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Renalytix Plc - RNLX

Newsfile April 21, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Renalytix Plc - RNLX

PR Newswire April 11, 2022

Renalytix plc Issue of shares

GlobeNewswire April 8, 2022

Renalytix plc successful completion of $30.0 million financing package

GlobeNewswire April 8, 2022

Renalytix announces a $30.0 million financing package

GlobeNewswire March 31, 2022

Renalytix Reports Financial Results for Second Quarter of Fiscal Year 2022

GlobeNewswire March 31, 2022

Confirmation of Appointment of Timothy Scannell to Renalytix Board of Directors

GlobeNewswire March 30, 2022